The negative predictive values determined from the current colposcopy population with a high incidence of disease cannot be assumed to apply to a screening population with a low incidence of disease.
Historically, as new technology is validated on a known cohort, it is then applied to a prospective screening cohort in a linked or unlinked (e.g., HIV screening) method, with or without reporting, and with or without randomization (e.g., CF).
The classification model is applied to a virtual screening of anticonvulsant compounds by analyzing a data set of molecules reported in the literature.
In our opinion, the OCT parameters that correlate with a clinical diagnosis of CSME are insufficiently defined or validated to be applied to a retinal screening programme.
If further validated and improved in future studies, these results may be applied to a feasible screening regimen, either in high-risk population or even in the general population, to detect this cancer at potentially curative stages.
Our results show the utility of combining focused small molecule derivation, applied to a biological screen using the zebrafish model, to identify new compounds with desired target activity and specificity.
The method is applied to a virtual screen of a commercial library of ∼450,000 available compounds.
Furthermore, although the genetic perturbations are limited to MAPK signaling genes, the methods could be applied to a wider screen or population-based analysis to identify additional pathway relationships.
Before our COD system described here can be applied to a combinatorial screen, further engineering of the compound supply (via the carousel and its integration with conventional liquid handling systems) will be necessary to carry out automated large-scale experiments.
In Vogt and Bajorath [12], the same weighting scheme is used to bias two distinct virtual screening algorithms and applied to a high-throughput screening (HTS) data set of cathepsin B inhibitors.
